[{"id":"7541215a-5741-4ef5-b1af-d11fad045e6c","acronym":"KEYNOTE-E72","url":"https://clinicaltrials.gov/study/NCT06016920","created_at":"2023-08-30T14:08:44.837Z","updated_at":"2025-02-25T16:19:04.091Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06016920 - KEYNOTE-E72","lead_sponsor":"Nykode Therapeutics ASA","biomarkers":" PD-L1 • IFNG","pipe":"","alterations":" ","tags":["PD-L1 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • abipapogene suvaplasmid (VB10.16)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 12/19/2023","start_date":" 12/19/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-12-17"},{"id":"7558045a-8e07-41e2-b7b2-b033022f966d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06099418","created_at":"2023-10-25T19:13:59.855Z","updated_at":"2024-07-02T16:34:26.647Z","phase":"Phase 2","brief_title":"Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.","source_id_and_acronym":"NCT06099418","lead_sponsor":"Nykode Therapeutics ASA","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • abipapogene suvaplasmid (VB10.16)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 04/18/2024","start_date":" 04/18/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-06-13"},{"id":"63c2f4c9-2f86-4de8-8b35-680b1bb67d2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04405349","created_at":"2021-01-18T21:14:59.324Z","updated_at":"2024-07-02T16:35:26.097Z","phase":"Phase 2","brief_title":"Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer","source_id_and_acronym":"NCT04405349","lead_sponsor":"Nykode Therapeutics ASA","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • abipapogene suvaplasmid (VB10.16)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 11/24/2023","primary_completion_date":" 11/24/2023","study_txt":" Completion: 11/24/2023","study_completion_date":" 11/24/2023","last_update_posted":"2023-12-15"}]